Citi lowered the firm’s price target on Stryker to $330 from $342 and keeps a Buy rating on the shares. In a note previewing the Q3 earnings reports, the analyst says that in a short three months, medical technical investing has moved from excitement over recovering procedures and an improving macro environment to fear about the potential impact of GLP-1s and anti-corruption policies in China. When concerns over currency moves and the consumer are added, “it is a recipe for a tough stock environment…but this is where the opportunities can be had,” the analyst tells investors in a research note. Citi’s top picks are Boston Scientific (BSX), DexCom (DXCM) and Stryker (SYK).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SYK:
- Stryker to announce financial results for its third quarter of fiscal year 2023
- Early notable gainers among liquid option names on September 28th
- Stryker management to meet with Piper Sandler
- Stryker: Pangea Systems including Femur,Tibia gets 510k clearance from the FDA
- Stryker upgraded to Buy from Neutral at BofA